

# atovaquone (MEPRON)

# **Diagnoses Considered for Coverage:**

- Pneumocystis pneumonia (PCP) in immunocompromised patient, prevention/suppression
- Pneumocystis pneumonia (PCP) in immunocompromised patient, treatment
- Toxoplasmosis in immunocompromised patient, prevention
- Toxoplasmosis in immunocompromised patient, treatment
- Babesiosis, treatment
- Toxoplasma retinochoroiditis in immunocompetent patient, treatment

# **Coverage Criteria:**

# For pneumocystis carinii pneumonia (PCP):

- Patient is immunocompromised, is receiving myelosuppressive agent, or is at high risk for infection, **and**
- Inadequate response, intolerable side effect, or contraindication to trimethoprim with sulfamethoxazole (Bactrim, Septra), and
- Dose does exceed 1500 mg per day.

## Coverage Duration:

- Prophylaxis or suppression: one year
- **Treatment**: 21 days

## For diagnosis of toxoplasmosis:

# For immunocompromised patient

- Patient is immunocompromised (e.g., HIV infection, neutropenia), or
  patient is receiving myelosuppressive agent, or patient is at high risk for
  infection (e.g. recent transplant patient), and
- Being used for:
  - Treatment or secondary prevention of toxoplasmosis, or
  - Primary prevention, and
    - Inadequate response, intolerable side effect, or contraindication to trimethoprim/sulfamethoxazole (Bactrim, Septra, TMP/SMX), and
- Dose does not exceed 3000 mg per day.

### Coverage Duration:

- Prophylaxis or suppression: one year
- Treatment: 6 weeks

### For immunocompetent patient

- Inadequate response, intolerable side effect, or contraindication to trimethoprim/ sulfamethoxazole (Bactrim, Septra, TMP/SMX), and
- Dose does not exceed 3000 mg per day.

Coverage Duration: 12 weeks

# For diagnosis of active Babesia infection:

- Dose does not exceed 1500 mg per day, and
- Evidence of CURRENT Babesia infection by one of the following:
  - Blood smear is positive for *Babesia microti* parasites, **or**
  - Blood sample by PCR is positive for Babesia microti DNA, or
  - Blood sample by FISH is positive for *Babesia microti* RNA.

Coverage Duration: 10 days

Effective Date: 5/31/2023